Pamrevlumab

Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.[2]

Pamrevlumab
Monoclonal antibody
Type?
SourceHuman
TargetCTGF
Clinical data
Other namesFG-3019
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10018N1718O2086S48
Molar mass147050.38 g·mol−1

This drug was developed by FibroGen, Inc.[3]

References

  1. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID 32447983. S2CID 218873298.
  3. Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.